Gleave ME - Search Results

1

Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.

Wafa LA, Palmer J, Fazli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS. Wafa LA, et al. Among authors: gleave me. Hum Pathol. 2007 Jan;38(1):161-70. doi: 10.1016/j.humpath.2006.07.003. Epub 2006 Sep 25. Hum Pathol. 2007. PMID: 16997353

2

[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].

Bruchovsky N, Goldenberg SL, Rennie PS, Gleave M. Bruchovsky N, et al. Urologe A. 1995 Sep;34(5):389-92. Urologe A. 1995. PMID: 7483155 Review. German.

3

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Gleave ME, et al. J Urol. 1996 Jan;155(1):213-9. J Urol. 1996. PMID: 7490838 Clinical Trial.

4

Control of tumor progression by maintenance of apoptosis.

Bruchovsky N, Snoek R, Rennie PS, Akakura K, Goldenberg LS, Gleave M. Bruchovsky N, et al. Prostate Suppl. 1996;6:13-21. Prostate Suppl. 1996. PMID: 8630223 Review.

5

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD. Gleave ME, et al. Semin Urol Oncol. 1996 May;14(2 Suppl 2):39-45; discussion 46-7. Semin Urol Oncol. 1996. PMID: 8725890 Review.

6

[Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].

Gleave M, Santo N, Rennie PS, Goldenberg SL, Bruchovsky N, Sullivan LD. Gleave M, et al. Prog Urol. 1996 Jun;6(3):375-85. Prog Urol. 1996. PMID: 8763692 French.

7

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Sato N, et al. Among authors: gleave me. J Steroid Biochem Mol Biol. 1996 May;58(2):139-46. doi: 10.1016/0960-0760(96)00018-0. J Steroid Biochem Mol Biol. 1996. PMID: 8809195

8

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. Sato N, et al. Among authors: gleave me. Cancer Res. 1997 Apr 15;57(8):1584-9. Cancer Res. 1997. PMID: 9108464

9

Re: Editorial comment.

Goldenberg SL, Gleave ME, Bruchovsky N, Rennie P. Goldenberg SL, et al. Among authors: gleave me. J Urol. 1997 Jun;157(6):2267. doi: 10.1016/s0022-5347(01)64759-1. J Urol. 1997. PMID: 9146650 No abstract available.

10

Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP.

Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME. Sato N, et al. Among authors: gleave me. J Biol Chem. 1997 Jul 11;272(28):17485-94. doi: 10.1074/jbc.272.28.17485. J Biol Chem. 1997. PMID: 9211894 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

664 results

Search Page

Filters